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Distinguishing Between Primary and M etastatic Tumor Cells 
It h as ncvcr becn c1car, says G racc Ga nd crup of thc Uni vcrsity 
of Cali forn ia College of M edi cinc, Irvine, w hy mctas tati c ca ncer 
cell s are so lethal. " Arc metas tatic cell s thc same as cells from thc 
prin1a ry tumor o r is th crc somcthing intrinsicall y d iffc rcnt?" she 
asks . So shc, Am y Ncw burgcr, andJcrry McCullough g rcw cells 
fron, prim ary and mctastatic melanomas fro m thc same pati cnt 
in nude mice and studi cd their g rowth charactcrist ics . "To our 
knowledgc, thi s is thc first timc that cclls fro m primary and 
metastatic tum o rs fro m thc sa mc patient were com pared in thcsc 
types of assays," Gand erup rcmarks. 
Gandcrup, N ewburgcr, and McCull ough first lookcd at the 
cell cycles of cclls from the primary and metastatic tum ors. T hcy 
expected that the cell s from the metastatic tumors would d ividc 
more qui ckl y . But, to their surpri sc, th ey found that thc cell cycle 
time for th c cell s from the mctastat ic tumors was 188 hours, 
w h ercas it was onl y 60 hours fo r thc cell s from prim ary tumors. 
T h e period w hcn DNA is synthesizcd was 33 hours in cell s from 
thc m ctas tascs but just 8 hours in cclls from the primary tumor 
cells. 
In add ition to growing morc slowly, thc ccll s from thc mcta-
static l11e1anomas also were much easier to transplant. At the 
seventh passagc, 69% of cclls from thc mctasta tic tumo rs grcw, 
w hcrcas onl y 42% of the cel ls from thc primary tumor did . Whcn 
Ga ndcrup and hcr assoclatcs cxa mincd thc tumors, they noticcd 
that when thc prim ary tUl110rs wcre transplantcd into nudc micc, 
these tumors had areas of necrosis w hcn they were much smaller 
in size than thc sizc at which nccrosis occurrcd when metastatic 
tu mo r cell s were tra nsplanted. Ganderup specu lates that the meta-
static tumors may be morc ab lc to devclop blood suppli es by 
initiatin g the fo rm ation of ncw blood vessels. 
Ga nderup says she cannot genera li ze from th cse observations. 
But, fo r this patient, at Icast, she answered her o riginal question. 
T herc is clearly a difference in growth characteristics bctwecn 
primary and metas tatic melanoma cells cven in the samc patient. 
A N ew, Potent Vasodilator 
A substance that was first thou ght to be a new neuropeptide now 
turns out to bc an as tonishin gly potcnt and long-acting vasod i-
lator. Susan B rain , of th e MRC C lini ca l Resca rch Ccntrc in Har-
row, E ngland , J ohn T ippins and Howard M orris of Imperial 
Collegc in Lond on , lain Macintyre of thc Roya l Postgradu atc 
Medica l School in Lond on , and Timothy Wi lli ams of Brain 's 
laboratory at the MRC, repo rt in this issue on the substancc's 
effects on hum an skin . 
In 1980, resca rchers fo und that the gcnc cod ing for calcitonin 
in rats also codcs for a 37 amino acid pcp tidc, which was ca llcd 
ca lcitonin gcnc-rclatcd peptid e (CGRP). At thc timc, no onc kn ew 
w hat thc substance did o r w hcrc in the body it was loca tcd . T hcsc 
investigators made flu o resccnt antibodics to CG RP and discov-
ered that, in thc rat , it occurs in nervcs. So CG RP was thought 
to b e a Il curopcptidc. 
N ext, M acl ntyrc dccidcd to sec ifCG RP was prescnt in thyi·o id 
tiss u e (w hi ch makcs ca lcitonin) from paticnts with medull ary 
ca rcinomas. H e discovcrcd a substance, a human CG RP, th at was 
sl ightly diffcrent from the rat CG RP but still appcared to bc 
associatcd mainl y with ncrves. T hen he gavc thc human CGR P 
to Brain to dctcrminc if it had any vasod ilatory cffects. 
"Wc first inj ccted it into rabb it skin and found , contrary to 
anything th at had been found before, that it was a potent vaso-
dilator," Brain remarks. "Then we injectcd into our own fo rc-
arms and found that it ca uscd loca l red ness. That led us to our 
prcsent stud y. 
"Wc wanted to see if CGRP was inducing rcdness by affecting 
blood fl ow. Wc also werc intcrcstcd in com paring it to othcr 
vasodilators," Brain says. What they lea rned is that CGRP is an 
extremcl y potcnt, pers istent vasodi lator in human skin . [t induces 
an erythema that is 1110re pcrsistcnt than other known vasodi la-
tors-histaminc, prostaglandin E2 and [2, substancc P, and vaso-
activc intcstina l peptide. It also caused increased blood fl ow for 
sevcra l hours. "We don't know how CGRP is brokcn down, " 
Brain rcmarks. 
Accordin g to Brain, CGRP could havc clinica l uses. It raiscs 
blood pressure so it could bc uscd as an agent in hypotension. 
Another possible usc mi ght bc as a trcatmcnt for Raynaud's syn-
dromc. Shc suggests, in fact, that Raynaud 's synd rome mi ght bc 
caused by the release of insufficient quanti tics of CGRP by the 
ncrves. Still ano th er possiblc usc for CG RP mi ght be as a corona ry 
vasod ilator to trea t co ronary spasms. 
T he CGRP, then, is on ly beginn in g to bc understood and its 
uscs probed . But beca use it is so potent, it un doubted ly wi ll prove 
clini ca ll y useful. 
Immune Surveillance and Skin Cancer 
Natura l ki ller (NK) cclls, wh ich do not require priming by an-
tibodies, are thought to be cru cial to thc immunc survcillancc 
against cancer. N ow Akira Koh chi ya ma, Daisuke Oka, and Hi-
roaki U ck i of Kawasa ki M edi cal Schoo l in Okaya ma, Japan report 
in this iss ue that NK cells arc rcadi ly detcctcd in squamous cell 
ca rcinom as of the sk in . 
NK cell s freq uently occur in contact w ith tumor cells such as 
Hodgkin 's lympho m a, non-Hodgkin 's lymphoma , and carci-
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nOlllas of the li ver, bre:lst, lungs and k idneys . So Ko hchjya ma, 
Oka, and Ueki looked fo r NK cell s in frozen sectio ns o f human 
sq uamous cell ca rcin o mas. Al tho ug h most of the imm un e syste m 
cell s detected in these sectio ns were T cell s, they did find N K 
THE JOU ltNAL OF INVESTIGATIV E DERMATOLOGY 
ce ll s. Since these studies are the first to report that NK cells were 
fou nd in a cutaneous m ali gnancy, they support the hypothesis 
that NK cell s participate in the immune defense agai nst cutaneous 
sq uam o us cell ca rcino m a. 
Vascular Damage in Autoimmune D iseases 
T he major ca use of vascul ar damage in auto immune d iseases, 
accord ing to conventi onal wisdo m , is due to deposition of im-
mune complexes. But, say Rory M arks, Mari a Czernieck i, and 
Ronald Penn y of St. Vincent 's H ospi tal in Sydney, Australi a, the 
existence of th is mechan ism in hum an d isease is not clea rl y es-
tablished . T hese investiga tors postul ate that another mecha-
nism-antibody dependent ce ll ular toxicity-m ig ht acco unt for 
vascul ar damage in autoimmune diseases. In this issue, they pres-
ent in vitro evidence to support their hypothes is. 
Marks, Czern iecki , and Penny explain that they question the 
immune complex hypothesis in part because it simpl y is not co n-
sistent with all the ev idence. Vascu lar damage ca n occur w itho ut 
any evidence of immune co mplexes. Moreover, there ca n be vas-
cular damage w ith an accumulat io n of lymp hocytes rath er than 
the neutro phils that wo uld be ex pected if th e damage we re due 
to immune complexes . Finall y, o thers have suggested that anti-
body dependent e) lul ar toxi cit y is in vo lved in the pathogenes is 
of hum an au to immune diseases and th at it could ca use vascular 
destruction. 
T he investigato rs studi ed the ability of antibody dependent 
cellular toxicity to dama ge human micro vascul ar end o theli al cells 
in vitro, since these cells arc m ost li kely to be affected in patients 
with auto immune di sease . Althoug h, as M arks , Cze rniecki , and 
Penn y point o ut , their in vit ro findin gs do not demonstrate that 
the mechanism o perates in vivo. T hey have recentl y found that 
in v ivo K lymphocy tes, w hi ch require antibod ies for priming and 
w hi ch medi ate antibody depe nden t cellul ar toxicity, are often 
p resent in sk in bio psies of patients w ith prog ressive system ic 
scleros is (PSS) . M any of these (PSS) patients have a circulatin g 
antibody that w ill medi ate antibody depend ent cellul ar tox icity 
in their in v it ro m odel. So it is quite possible that an tibod y de-
penden t cellul ar tox icity is a major ca use o f vascul ar da m age in 
autoim mune disease. 
Erratum 
The item "How Keratinocytes and Lymphocytes Interact" in 
Ju ly's " In T hi s Iss ue ... ," las t sentence, fo urth parag raph , sho uld 
read : In add iti o n, the lymphocytes m ay be inhibi ted from dividin g 
in part beca use their IL-2 prod uct is indirectl y impaired by TGE2 
secretio n , w hi ch is in creased by y-interfero n. 
